Meeting
2020 Gastrointestinal Cancers Symposium
Regorafenib with TAS-102 (REGOTAS) in metastatic colorectal cancer patients who progressed after at least two standard therapies: Efficacy and safety results of a multicenter phase I study (REMETY).
Authors
Markus H. Moehler
Johannes Gutenberg-University Clinic, Mainz, Germany
Markus H. Moehler , Alexander Stein , Jorg Trojan , Jens Uwe Marquardt , Julia Quidde , Oliver Waidmann , Arndt Weinmann , Marcus Woerns , Helge Schroeder , Martin Maenz , Aysun Karatas , Friedrich Foerster
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Anal and Colorectal Cancer
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03305913
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 158)
Abstract #
158
Poster Bd #
G22
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Combination of hSTC810 and capecitabine therapy in metastatic colorectal cancer with resistance or intolerance to oxaliplatin and irinotecan-based chemotherapy: A single arm, phase 1b/2, multicenter study.
First Author: Jiwon Lee
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Regorafenib, ipilimumab, and nivolumab (RIN) in chemotherapy-resistant MSS metastatic colorectal cancer (mCRC).
First Author: Marwan Fakih
Poster
2022 ASCO Annual Meeting
Pembrolizumab (pembro) plus binimetinib (bini) with or without chemotherapy (chemo) for metastatic colorectal cancer (mCRC): Results from KEYNOTE-651 cohorts A, C, and E.
First Author: Eric Xueyu Chen
Poster
2019 ASCO Annual Meeting
A phase II study of lenvatinib in patients with metastatic colorectal cancer refractory to standard chemotherapy: LEMON study (NCCH1503).
First Author: Hirokazu Shoji